Avodart 0.5mg Soft Capsule
PDF Leaflet Revision Date: 28 February 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of Benign Prostatic Hyperplasia (BPH).
Dosage (summary)
1 capsule (0.5 mg) orally once daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in women; potential risk to male fetus.
Key Drug Interactions
- CYP3A4 inhibitors may increase dutasteride levels
Contraindications
- Hypersensitivity to dutasteride
- Women
- Children
Common side effects
- Impotence
- Dizziness
- Altered libido
- Ejaculation disorders
Counselling Points
- Avoid contact with leaking capsules
- Report breast changes
- Use contraception during sexual intercourse
Serious warnings
- Increased risk of high-grade prostate cancer
- Cardiovascular events with alpha blockers
Important Disclaimer
The Avodart 0.5mg Soft Capsule professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
